摘要
目的探讨武汉市第三医院新型冠状病毒肺炎(COVID-19)患者治疗期间发生药物性肝功能异常的一般规律和特点,为临床安全用药提供参考。方法收集2020年1月27日—2020年3月8日武汉市第三医院出现的药物致肝功能异常的COVID-19患者资料,对患者用药、肝功能检查值、治疗和转归情况进行回顾性分析。结果COVID-19患者治疗过程中出现药源性肝功能异常的男性较多(P<0.01),且51~70岁是高发阶段;60%以上的患者应用治疗COVID-19各类药物均达到2种及以上,对症治疗药物合并用药3种及以上药物达到51.96%。结论COVID-19诊疗过程中,警惕中老年男性患者联合用药造成的药物性肝功能异常,减轻肝脏负担,加强用药监护并及时对症处理。
Objective To investigate the general rules and characteristics of drug-induced liver dysfunction during the treatment of COVID-19, and to provide references for safe clinical use. Methods Data of COVID-19 patients with drug-induced abnormal liver function during treatment in The Third Hospital of Wuhan from January 27, 2020 to March 3, 2020 were collected. Results During the treatment of COVID-19, drug-induced liver dysfunction was more common in males(P < 0.05), and the incidence was high between 51 and 70 years old, more than 60% of the patients received two or more drugs for treatment COVID-19, and the combination of three or more symptomatic drugs reached 51.96%. Conclusion During the diagnosis and treatment of COVID-19, doctors should be on guard against the drug-induced liver dysfunction caused by the combination of drugs in middle-aged and elderly male patients, to reduce the burden on the liver, and strengthen medication monitoring and timely supply symptomatic treatment.
作者
李颖
邹吉利
江洁
朱丽
熊迪
LI Ying;ZOU Ji-li;JIANG Jie;ZHU Li;XIONG Di(Department of Pharmacy,The Third Hospital of Wuhan,Wuhan 430060,China)
出处
《现代药物与临床》
CAS
2020年第10期2073-2078,共6页
Drugs & Clinic
基金
国家自然科学基金资助项目(81603352)。
